Decreased langerhans cell responses to IL-36γ: Altered innate immunity in patients with recurrent respiratory papillomatosis

Molecular Medicine

Volumn 20, Issue JULY-DECEMBER 2014, 2014, Pages 372-380

  Devoti, James ^a,c   Hatam, Lynda ^a,c   Lucs, Alexandra ^a,d   Afzal, Ali ^b   Abramson, Allan ^a,d   Steinberg, Bettie ^b,d   Bonagura, Vincent ^a,b,c  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b Elmezzi Graduate School of Molecular Medicine   (United States)

^c Division of Allergy/Immunology   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCL1 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 36 GAMMA; INTERLEUKIN 6; LANGERIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; T6 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN; CCL1 PROTEIN, HUMAN; IL36G PROTEIN, HUMAN;

ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN TISSUE; IMMATURE LANGERHANS CELL; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; KERATINOCYTE; LANGERHANS CELL; MONOCYTE; NEWBORN; PAPILLOMAVIRUS INFECTION; PROTEIN EXPRESSION; PROTEIN SECRETION; RECURRENT RESPIRATORY PAPILLOMATOSIS; RECURRENT VIRUS INFECTION; REGULATORY T LYMPHOCYTE; UPREGULATION; CELL CULTURE; GENETICS; IMMUNOLOGY; LARYNX; RESPIRATORY TRACT INFECTION; VIROLOGY;

CELLS, CULTURED; CHEMOKINE CCL1; HUMAN PAPILLOMAVIRUS 11; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-1; INTERLEUKIN-1BETA; KERATINOCYTES; LANGERHANS CELLS; LARYNX; PAPILLOMAVIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84921905376     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2014.00098     Document Type: Article

References (66)

1. DeVoti JA, et al. (2004) Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis. Clin. Diagn. Lab. Immunol. 11:538–47.
2. Bonagura VR, et al. (2009) KIR3DS1, KIR2DS1, and KIR2DS5 protect against the development of severe recurrent respiratory papillomatosis (RRP) in HPV-6/11-Infected patients. J. Allergy Clin. Immunol. 123:S165.
3. Bonagura VR, et al. (2010) Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS. 118:455–70.
4. DeVoti JA, et al. (2008) Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: A paired microarray analysis. Mol. Med. 14:608–17.
5. Vigne S, et al. (2012) IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood. 120:3478–87.
6. Mutamba S, Allison A, Mahida Y, Barrow P, Foster N. (2011) Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur. J. Immunol. 42:607–17.
7. Blumberg H, et al. (2007) Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med. 204:2603–14.
8. Johnston A, et al. (2011) IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol. 186:2613–22.
9. Vigne S, et al. (2011) IL-36R ligands are potent regulators of dendritic and T cells. Blood. 118:5813–23.
10. Marrakchi S, et al. (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 365:620–8.
11. Towne JE, Sims JE. (2012) IL-36 in psoriasis. Curr. Opin. Pharmacol. 12:486–90.
12. Dinarello CA. (2013) Overview of the interleukin-1 family of ligands and receptors. Semin. Immunol. 25:389–93.
13. Carrier Y, et al. (2011) Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J. Invest. Dermatol. 131:2428–37.
14. Steinberg BM, Abramson AL, Meade RP. (1982) Culture of human laryngeal papilloma cells in vitro. Otolaryngol. Head Neck Surg. 90:728–35.
15. Kashima HB, Leventhal B, Mounts P, Papilloma Study Group. (1985) Scoring system to assess severity and course in recurrent respiratory papillomatosis. In: Papillomavirus: molecular and clinical aspects: proceedings of the Burroughs-Wellcome- UCLA Symposium held in Steamboat Springs, Colorado, April 8-14, 1985. Howley PM, Broker TR (eds). Alan R. Liss, New York.
16. Abramson AL, et al. (1992) Clinical effects of photodynamic therapy on recurrent laryngeal papillomas. Arch. Otolaryngol. Head Neck Surg. 118:25–29.
17. Wu R, Coniglio SJ, Chan A, Symons MH, Steinberg BM. (2007) Up-regulation of Rac1 by epidermal growth factor mediates COX-2 expression in recurrent respiratory papillomas. Mol. Med. 13:143–50.
18. Kis-Toth K, et al. (2013) Monocyte-derived dendritic cell subpopulations use different types of matrix metalloproteinases inhibited by GM6001. Immunobiology. 218:1361–9.
19. Chung DJ, et al. (2013) Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cellbased immunotherapy. J. Transl. Med. 11:166.
20. Lian LH, Milora KA, Manupipatpong KK, Jensen LE. (2012) The double-stranded RNA analogue polyinosinic-polycytidylic acid induces keratinocyte pyroptosis and release of IL-36gamma. J. Invest. Dermatol. 132:1346–53.
21. Hatam LJ, et al. (2008) CD4(+)Foxp3(+)CD127(+low) T-Regulatory cells are increased in HPV infected papillomas in patients with recurrent respiratory papillomatosis (RRP). J. Allergy Clin. Immunol. 121:S211.
22. Hatam LJ, et al. (2012) Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/ PD-L1/L2 expression. Clin. Cancer Res. 18:1925–35.
23. Geissmann F, et al. (2002) Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J. Exp. Med. 196:417–30.
24. Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. (2004) Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J. Biol. Chem. 279:13677–88.
25. Zhang C, Zhang X, Chen XH. (2014) Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance. Clin. Rev. Allergy Immunol. 2014, Mar 20 [Epub ahead of print].
26. Weng Z, Patel AB, Vasiadi M, Therianou A, Theoharides TC. (2014) Luteolin inhibits human keratinocyte activation and decreases NF-êB induction that is increased in psoriatic skin. PLoS One. 9:e90739.
27. Junk DJ, Bryson BL, Jackson MW. (2014) HiJAK’d signaling; the STAT3 paradox in senescence and cancer progression. Cancers (Basel). 6:741–55.
28. Guggino G, et al. (2014) Targeting IL-6 signalling in early rheumatoid arthritis is followed by Th1 and Th17 suppression and Th2 expansion. Clin. Exp. Rheumatol. 32:77–81.
29. Bonagura VR, Hatam L, DeVoti J, Zeng FF, Steinberg BM. (1999) Recurrent respiratory papillomatosis: Altered CD8(+) T-cell subsets and T(H)1/T(H)2 cytokine imbalance. Clin. Immunol. 93:302–11.
30. Rosenthal DW, et al. (2006) Recurrent respiratory papillomatosis (RRP): Increased T(H)2-like chemokine expression. J. Allergy Clin. Immunol. 117:S104.
31. Rosenthal DW, Devoti JA, Steinberg BM, Abramson AL, Bonagura VR. (2012) TH2-like chemokine patterns correlate with disease severity in patients with recurrent respiratory papillomatosis. Mol. Med. 18:1338–45.
32. Bonagura VR, et al. (2004) HLA alleles, IFNgamma responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis. Human Immunol. 65:773–82.
33. Ramadas RA, Ewart SL, Medoff BD, LeVine AM. (2011) Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am. J. Respir. Cell Mol. Biol. 44:134–45.
34. Chustz RT, et al. (2011) Regulation and function of the IL-1 family Cytokine IL-1F9 in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 45:145–53.
35. Towne JE, et al. (2011) Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL- 36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J. Biol. Chem. 286:42594–602.
36. Steinman RM. (1991) The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271–96.
37. Hart DN. (1997) Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90:3245–87.
38. Matzinger P. (1994) Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991–1045.
39. Noel W, et al. (2004) Alternatively activated macrophages during parasite infections. Trends Parasitol. 20:126–33.
40. McGuirk P, McCann C, Mills KH. (2002) Pathogenspecific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exp. Med. 195:221–31.
41. Shortman K, Liu YJ. (2002) Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2:151–61.
42. Shirakata Y. (2010) Regulation of epidermal keratinocytes by growth factors. J. Dermatol. Sci. 59:73–80.
43. Werner S, Krieg T, Smola H. (2007) Keratinocytefibroblast interactions in wound healing. J. Invest. Dermatol. 127:998–1008.
44. Pastore S, Mascia F, Girolomoni G. (2006) The contribution of keratinocytes to the pathogenesis of atopic dermatitis. Eur. J. Dermatol. 16:125–31.
45. Bergmann C, et al. (2008) T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin. Cancer Res. 14:3706–15.
46. Banchereau J, et al. (2000) Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767–811.
47. Banchereau J, et al. (2003) Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann. N. Y. Acad. Sci. 987:180–7.
48. Caux C, et al. (1997) CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colonystimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood. 90:1458–70.
49. Steinman RM, Turley S, Mellman I, Inaba K. (2000) The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191:411–6.
50. Iwasaki A, Kelsall BL. (1999) Freshly isolated Peyer’s patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J. Exp. Med. 190:229–39.
51. Enk AH, Angeloni VL, Udey MC, Katz SI. (1993) Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol. 151:2390–8.
52. Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD. (1995) IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J. Immunol. 154:1280–6.
53. Romani N, et al. (2006) Epidermal Langerhans cells—changing views on their function in vivo. Immunol. Lett. 106:119–25.
54. Elias AN, Nanda VS, Barr RJ. (2003) CD1a expression in psoriatic skin following treatment with propylthiouracil, an antithyroid thioureylene. BMC Dermatol. 3:3.
55. Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ. (2005) Epidermal Langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity. 23:611–20.
56. Klechevsky E, et al. (2008) Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity. 29:497–510.
57. Bennett CL, et al. (2011) Langerhans cells regulate cutaneous injury by licensing CD8 effector cells recruited to the skin. Blood. 117:7063–9.
58. James E, et al. (2010) Human papillomavirus (HPV)-specific T-cells recognizing dominant E2/E6 epitopes elicit reduced IFN-ã in patients with recurrent respiratory papillomatosis (RRP). J. Allergy Clin. Immunol. 125:S.
59. James EA, et al. (2011) Papillomavirus-specific CD4(+) T cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis. J. Immunol. 186:6633–40.
60. Chopin M, et al. (2013) Langerhans cells are generated by two distinct PU.1-dependent transcriptional networks. J. Exp. Med. 210:2967–80.
61. Chopin M, Nutt SL. (2014) Establishing and maintaining the Langerhans cell network. Semin. Cell. Dev. Biol. 2014, Feb 7. [Epub ahead of print].
62. Bonagura VR, et al. (2010) Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis. Human Immunol. 71:212–9.
63. Gombert M, et al. (2005) CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J. Immunol. 174:5082–91.
64. Henry E, et al. (2008) Dendritic cells genetically engineered to express IL-10 induce long-lasting antigen-specific tolerance in experimental asthma. J. Immunol. 181:7230–42.
65. Dieu-Nosjean MC, et al. (2000) Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J. Exp. Med. 192:705–18.
66. Merad M, et al. (2002) Langerhans cells renew in the skin throughout life under steady-state conditions. Nat. Immunol. 3:1135–41.